44 results
6-K
BYSI
BeyondSpring Inc
18 Mar 24
Current report (foreign)
8:30am
in innovative drug research and development. Dr. Lu joined the Company in October 2021 as Senior Director of Pre-Clinical and was recently promoted
6-K
BYSI
BeyondSpring Inc
2 Feb 24
Current report (foreign)
4:30pm
of shares and per share data)
Six months ended June 30,
Revenue
Operating expenses
Research and development
General and administrative
Loss from
6-K
EX-99.1
BYSI
BeyondSpring Inc
30 Dec 21
Current report (foreign)
12:30pm
-L1 inhibitors + radiation in patients with seven cancer types.
Third Quarter Financial Results
Research and development (“R&D”) expenses were $8.5 … months ended September 30,
Nine months ended September 30,
Note
Revenue
Operating expenses
Research and development
General and administrative
Loss
6-K
EX-99.1
yn6xvbcqop4 s7
10 Sep 21
Current report (foreign)
8:30am
6-K
EX-99.1
zmop3
26 Aug 21
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
7:15am
6-K
EX-99.1
pvv0j0t8
5 Aug 21
Current report (foreign)
1:32pm
F-3
vzvvbchnt025gis20gjl
2 Jul 21
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
iya2usy kpzh56rbbhf
16 Jun 21
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
8:36am
6-K
qcnq9c76on7gf r1f1p
19 Mar 21
Current report (foreign)
4:05pm
6-K
EX-99.2
tubnolpk w1xpx1k81vz
9 Feb 21
Current report (foreign)
9:21am
424B5
3jq w9r3002
19 Nov 20
Prospectus supplement for primary offering
4:12pm
424B5
dx2 5rs9st3rztg
17 Nov 20
Prospectus supplement for primary offering
4:19pm
6-K
EX-99.1
4zn1nbz1ul7 8tc
17 Nov 20
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
8:06am
6-K
EX-99.1
47s2 0tucw
16 Nov 20
Current report (foreign)
7:22am
6-K
2kpmwziv afnpa
16 Nov 20
Current report (foreign)
7:22am
F-3
ksptl25s 0y
3 Nov 20
Shelf registration (foreign)
8:24am